Newer heart valves may let more people avoid surgery
of Medicine on Saturday and were to be discussed at an American College of Cardiology conference in New Orleans on Sunday.
In one study, about 1,000 patients were given standard surgery or an expandable Edwards Lifesciences valve. After one year, 15 percent of the surgery group and 8.5 percent of the others had died, suffered a stroke or needed to be hospitalized again.
In the other study, 1,400 patients were given surgery or a Medtronic expandable valve. Based on partial results, researchers estimated that after two years, 6.7 percent of the surgery group and 5.3 percent of the others had died or suffered a disabling stroke.
In both studies, certain problems were more common with surgery, including major bleeding and development of a fluttering heartbeat called atrial fibrillation. In the Medtronic study, 17 percent of expandable valve recipients later required a pacemaker versus 6 percent of people who had surgery.
Previous research suggests that overall costs are lower with expandable valves, which cost about $30,000 versus $5,000 for surgical ones, largely because they require much shorter hospital stays and caused fewer complications, said Cleveland, who also is a spokesman for the College of Cardiology.
In the United States, surgeries to replace aortic valves have been falling. Only about 25,000 are expected to be done this year and Cleveland expects that to drop by half next year and by half again in 2021.
He and other doctors say the expandable valves still need longer study to see if they hold up as well as surgical ones. Catheterbased approaches for problems with some other heart valves, such as the mitral valve, also have been developed or are in testing.